仁和药业(000650) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥1,284,684,485.67, representing a 2.20% increase year-over-year[7]. - Net profit attributable to shareholders decreased by 18.78% to ¥156,492,062.33 in Q3 2022[7]. - The net profit after deducting non-recurring gains and losses was ¥145,544,499.43, down 15.96% compared to the same period last year[7]. - The company's basic earnings per share decreased by 18.78% to ¥0.1118[7]. - The net profit for the third quarter was 183,483,640.01 CNY, compared to 178,411,314.21 CNY in the same period last year, representing an increase of approximately 0.6%[33]. - Operating profit for the quarter was 751,779,398.05 CNY, slightly down from 789,078,770.27 CNY, reflecting a decrease of approximately 4%[33]. - The total comprehensive income attributable to the parent company's owners was 456,457,572.95 CNY, down from 524,717,410.38 CNY, indicating a decrease of about 13%[37]. - The basic and diluted earnings per share for the quarter were both 0.3261 CNY, compared to 0.3748 CNY in the same period last year, reflecting a decrease of about 13%[37]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,211,809,888.83, an increase of 4.40% from the end of the previous year[7]. - Total liabilities amounted to CNY 851,567,690.54, down from CNY 980,999,158.26, a decrease of 13.2%[30]. - Non-current assets totaled CNY 3,041,789,320.76, up from CNY 2,852,235,894.69, indicating an increase of 6.6%[27]. - Shareholders' equity attributable to the parent company increased by 6.31% to ¥5,621,029,324.02[7]. - Shareholders' equity increased to CNY 6,360,242,198.29 from CNY 5,926,892,730.81, representing a growth of 7.3%[30]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥292,811,952.25, reflecting a 4.76% increase[7]. - Cash flow from operating activities generated a net inflow of 292,811,952.25 CNY, compared to 279,514,617.22 CNY in the previous year, showing an increase of about 4%[41]. - Cash received from tax refunds was 22,232,873.37 CNY, marking a 100% increase as it was the first time receiving tax refunds this period[15]. - The company received 22,232,873.37 CNY in tax refunds during the quarter, compared to 0.00 CNY in the previous year, indicating a significant increase in cash inflow from tax refunds[41]. - Cash flow from investment activities showed a net outflow of -1,846,879,295.38 CNY, a significant decrease of 703.51% compared to the previous year due to fewer redemptions of financial products[15]. - The company reported cash inflows from investment activities totaling 5,205,602,595.60 CNY, down from 7,676,536,813.38 CNY, a decrease of approximately 32%[41]. - Cash outflows from investment activities were 7,052,481,890.98 CNY, compared to 7,906,388,546.45 CNY, indicating a decrease of about 11%[41]. - The net cash flow from financing activities was -141,115,471.39 CNY, an improvement from -446,229,754.42 CNY in the previous year[41]. - The company’s cash and cash equivalents at the end of the period stood at 665,240,567.01 CNY, down from 1,329,067,643.32 CNY, a decrease of approximately 50%[41]. Operational Highlights - The company reported a significant increase of 537.42% in trading financial assets, totaling ¥2,011,666,716.00, due to increased investments in financial products[12]. - Financial expenses decreased by 57.45% to -19,779,356.25 CNY due to a reduction in large certificates of deposit compared to the same period last year[15]. - Interest income fell by 57.24% to 20,184,121.36 CNY, attributed to fewer large certificates of deposit compared to the previous year[15]. - Other income increased by 193.81% to 29,817,717.75 CNY, mainly from government subsidies for traditional Chinese medicine projects[15]. - Investment income rose by 58.66% to 28,930,031.49 CNY, primarily due to higher returns from financial products[15]. - Cash paid for various taxes increased by 61.73% to 451,007,677.10 CNY, mainly due to tax payments that were deferred under policy[15]. - The company reported a 56.68% decrease in cash paid for dividends and interest to 141,315,471.39 CNY compared to the previous year[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 122,511[20]. - The largest shareholder, Renhe Group, holds 23.24% of the shares, totaling 325,299,386 shares[20]. Future Outlook - Future outlook includes plans for market expansion and potential new product launches to drive revenue growth[32]. - The company reported a net profit margin improvement, with net profit increasing due to better cost management strategies[32]. Additional Information - The third quarter report of Renhe Pharmaceutical Co., Ltd. is unaudited[44].